Form 4: Olema Pharmaceuticals Director Sandra Horning Acquires 23,000 Stock Options
SEC Form 4 Filing
Director Sandra Horning acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.
Summary
- Sandra Horning, a director of Olema Pharmaceuticals, Inc., acquired 23,000 stock options on June 14, 2024.
- The exercise price of these options is $12.36.
- The options vest in 12 equal monthly installments starting from June 14, 2024, contingent upon continuous service.
- Full vesting occurs on the date of the Issuer's next annual meeting of stockholders if not fully vested before, also subject to continuous service.
- The options expire on June 14, 2034.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, and does not inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of the transaction: acquisition of 23,000 stock options and commencement of vesting period. |
| 06/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.